Mirum Pharmaceuticals (MIRM) AI Stock Analysis

• Market Cap: $3.62B
• Dividend Yield: N/A
• Average Volume (3M): 609.35K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.71
• Revenue Growth: 53.66%
• EPS Growth: 58.63%
• Country: US
• Employees: 334
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.05
• Shares Outstanding: 51,393,574
• 10 Day Avg. Volume: 667,564
• 30 Day Avg. Volume: 609,350
• PEG Ratio: 0.42
• Price to Book (P/B): 8.71
• Price to Sales (P/S): 5.83
• P/FCF Ratio: 210.57
• Enterprise Value/Market Cap: 1.14
• Enterprise Value/Revenue: 8.74
• Enterprise Value/Gross Profit: 10.93
• Enterprise Value/Ebitda: -751.40
• 1Y Price Target: $88.11
• Price Target Upside: 25.09% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9
• EPS Forecast (FY): -0.58
• Revenue Forecast (FY): $506.38M

• Rating: 51 Neutral
• Price Target: $70.00 ▼(-0.62% Downside)

Mirum Pharmaceuticals' overall stock score is driven by strong earnings call results, highlighting significant revenue growth and positive net income. However, financial performance concerns, particularly profitability and high leverage, weigh heavily on the score. Technical analysis and valuation also present challenges, with bearish momentum and a negative P/E ratio.

Positive Factors

Revenue Growth

Strong revenue growth indicates effective product adoption and market expansion, particularly with LIVMARLI, supporting long-term business sustainability.

International Expansion

Successful international expansion and reimbursement support enhance market reach and revenue diversification, contributing to long-term growth potential.

Clinical Pipeline Progress

Advancement in clinical trials, such as the VISTAS study, positions Mirum for future product approvals, strengthening its competitive edge and growth prospects.

Negative Factors

High Leverage

High leverage can limit financial flexibility and increase risk, potentially impacting the company's ability to invest in growth opportunities and weather economic downturns.

Profitability Challenges

Ongoing profitability challenges highlight difficulties in cost management, which could affect long-term financial health and shareholder returns.

Revenue Consistency

Revenue variability from international markets can lead to unpredictable financial performance, complicating planning and potentially affecting investor confidence.

Mirum Pharmaceuticals Business Overview & Revenue Model

Company Description

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with rare liver diseases. The company is primarily engaged in the development of treatments that address unmet medical needs in the field of hepatology. Its core products include Maralixibat, a drug designed for the treatment of cholestatic liver diseases, and other candidates targeting various liver conditions.

How the Company Makes Money

Mirum Pharmaceuticals generates revenue primarily through the sale of its approved products, including Maralixibat, which is marketed to healthcare providers for the treatment of cholestatic liver diseases. The company also engages in strategic partnerships and collaborations with other pharmaceutical firms to enhance its research and development capabilities, which can lead to milestone payments and royalties based on the success of its partnered programs. Additionally, Mirum may benefit from government grants or incentives aimed at supporting research in rare diseases, contributing to its overall revenue streams.

Mirum Pharmaceuticals Financial Statement Overview

Summary

Mirum Pharmaceuticals shows revenue growth but struggles with profitability, as indicated by negative net profit margins. The balance sheet reveals high leverage, posing financial risks, while cash flow management shows some strengths but also volatility.

Income Statement

Mirum Pharmaceuticals shows a positive revenue growth trend with a 9.93% increase in TTM, indicating potential market expansion. However, the company is struggling with profitability, as evidenced by negative net profit and EBIT margins. The gross profit margin is strong at 79.92%, but the negative net profit margin of -8.78% highlights ongoing challenges in managing operational costs.

Balance Sheet

The company has a high debt-to-equity ratio of 1.08, suggesting significant leverage which could pose financial risks. The return on equity is negative at -24.76%, indicating inefficiencies in generating returns for shareholders. The equity ratio is relatively low, reflecting a higher reliance on debt financing.

Cash Flow

Free cash flow has significantly improved, but the growth rate is negative, indicating volatility. The operating cash flow to net income ratio is 0.28, showing some ability to convert income into cash, but it remains low. The free cash flow to net income ratio is nearly 1, suggesting that the company is managing its cash flow effectively relative to its net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	471.79M	336.89M	186.37M	77.06M	19.14M	0.00
Gross Profit	377.04M	255.25M	139.34M	64.69M	17.23M	-623.00K
EBITDA	-5.49M	-48.97M	-136.49M	-122.85M	-65.39M	-102.31M
Net Income	-41.42M	-87.94M	-163.41M	-135.66M	-83.99M	-103.27M
Balance Sheet
Total Assets	785.12M	670.75M	646.62M	352.91M	294.65M	240.86M
Cash, Cash Equivalents and Short-Term Investments	375.55M	280.31M	286.33M	151.72M	156.54M	231.82M
Total Debt	318.76M	317.76M	308.14M	2.19M	2.61M	3.26M
Total Liabilities	493.07M	445.11M	397.95M	210.87M	174.44M	68.77M
Stockholders Equity	292.05M	225.64M	248.67M	142.04M	120.21M	172.09M
Cash Flow
Free Cash Flow	44.32M	9.33M	-91.05M	-120.41M	-151.78M	-89.30M
Operating Cash Flow	44.69M	10.32M	-70.94M	-120.14M	-132.76M	-89.08M
Investing Cash Flow	-24.32M	-90.13M	-107.20M	7.70M	48.55M	37.87M
Financing Cash Flow	36.48M	17.70M	336.60M	109.09M	73.47M	181.29M

Mirum Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 70.44
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MIRM, the sentiment is Neutral. The current price of 70.44 is below the 20-day moving average (MA) of 70.60, below the 50-day MA of 72.24, and above the 200-day MA of 56.11, indicating a neutral trend. The MACD of -0.20 indicates Negative momentum. The RSI at 47.87 is Neutral, neither overbought nor oversold. The STOCH value of 62.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for MIRM.

Mirum Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CPRX	83 Outperform	$2.77B	13.14	27.52%	―	25.56%	44.42%
ARWR	57 Neutral	$5.23B	-29.96	-34.80%	―	2816.21%	73.33%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MIRM	51 Neutral	$3.62B	―	-15.81%	―	53.66%	58.63%
APLS	51 Neutral	$2.46B	65.51	14.10%	―	42.11%	―
RARE	50 Neutral	$3.07B	―	-325.76%	―	20.63%	8.09%
IBRX	41 Neutral	$2.00B	―	―	―	1025.95%	52.91%

Mirum Pharmaceuticals Corporate Events

Mirum Pharmaceuticals Reports Robust Q3 Growth and Milestones

Mirum Pharmaceuticals’ latest earnings call painted a picture of robust growth and strategic advancements, with the company achieving significant revenue growth and positive net income for the first time. The sentiment was largely positive, highlighting the company’s successful international expansion and progress in its clinical pipeline. However, challenges remain in revenue consistency and the adoption of genetic testing in certain segments.

Mirum Pharmaceuticals Reports Strong Q3 2025 Growth

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company focused on transforming the treatment of rare diseases affecting children and adults, with a portfolio that includes three approved medications and a late-stage pipeline targeting several rare conditions.

Mirum Pharmaceuticals Advances in Fragile X Syndrome Treatment Study

Study Overview: Mirum Pharmaceuticals is conducting a Phase 2 clinical trial titled ‘Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of MRM-3379 in Male Participants With Fragile X Syndrome.’ The study aims to evaluate the safety and tolerability of MRM-3379 in males aged 16 to 45 with Fragile X Syndrome (FXS), with a parallel cohort of younger participants aged 13 to under 16 receiving open-label treatment. This research is significant as it explores a potential new treatment to alleviate symptoms of FXS, a genetic condition affecting cognitive and behavioral development.

Mirum Pharmaceuticals’ Volixibat Study: A Potential Breakthrough for PBC Itching

Study Overview: Mirum Pharmaceuticals is conducting a study titled A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Biliary Cholangitis. The study aims to assess the effectiveness and safety of volixibat in treating itching associated with Primary Biliary Cholangitis (PBC), a chronic liver disease. This research is significant as it could provide a new therapeutic option for managing symptoms and potentially impacting disease progression.

Mirum Pharmaceuticals Advances Phase 3 Study on Maralixibat for Cholestatic Pruritus

Mirum Pharmaceuticals is conducting a Phase 3 clinical study titled ‘Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Participants With Cholestatic Pruritus.’ The study aims to assess the safety and effectiveness of maralixibat in treating pruritus associated with cholestatic liver disease, a condition with limited treatment options.

Mirum Pharmaceuticals’ LEAP-US Study: A Long-Term Look at Livmarli’s Impact

Study Overview: The LEAP-US study, officially titled Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States, aims to evaluate the long-term safety and clinical outcomes of Livmarli in patients with Alagille syndrome (ALGS) or Progressive familial intrahepatic cholestasis (PFIC). This 5-year observational cohort study is significant as it seeks to provide crucial insights into the prolonged effects of Livmarli, a drug designed to manage these rare liver conditions.

Mirum Pharmaceuticals’ Volixibat Study: A Potential Game-Changer for PBC Treatment

Mirum Pharmaceuticals is conducting a study titled ‘A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Biliary Cholangitis.’ The study aims to assess the effectiveness and safety of the investigational drug volixibat for treating itching associated with Primary Biliary Cholangitis (PBC) and its potential impact on disease progression.

Mirum Pharmaceuticals’ Volixibat Study: A Potential Game-Changer for PSC Treatment

Mirum Pharmaceuticals is conducting a clinical study titled ‘A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis.’ The study aims to assess the effectiveness of volixibat, an investigational drug, in alleviating itching associated with Primary Sclerosing Cholangitis (PSC) and its potential impact on disease progression.

Mirum Pharmaceuticals Reports Strong Q2 Growth and Raises Guidance

Mirum Pharmaceuticals’ recent earnings call conveyed a positive sentiment, underscored by robust revenue growth, successful international expansion, and significant progress in its pipeline. Despite challenges such as high operating expenses and variability in international sales, the highlights of the call significantly outweighed the lowlights.

Mirum Pharmaceuticals Reports Strong Q2 2025 Growth

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing treatments for rare diseases affecting both children and adults, with a portfolio that includes three approved medications targeting rare liver and genetic disorders.